Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez
G
G
Department of Pediatric Haematology, Hacettepe University, Ankara, Turkey.
Jama
H
H
Ozsoylu
S
S
D000965:Antimony / Q000009:adverse effects; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced*; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D013012:Sorbitol / Q000031:analogs & derivatives*
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D013012:Sorbitol; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony